Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis

Fig. 5

(A) MDA-MB-231 xenograft model athymic nude mice treated with vehicle, doxorubicin, bocodepsin, or combination for 36 days. (B) Specific growth rates at day 36 depicting overall tumor growth inhibition (** = P < 0.01). (C) Senescence-associated β-galactosidase staining of frozen tissue collected at day 36. Scale 50 μm. H&E, Ki67, and cleaved-caspase 3 staining of formalin-fixed tissue collected at day 36. Representative images were taken at x20 magnification. Scale 100 μm

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us